The prevalence of multiple sclerosis in Israel based on validation of a health care organization database.
Epidemiology
Healthcare database
Multiple sclerosis
Prevalence
Validation
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 10 2024
23 10 2024
Historique:
received:
12
06
2024
accepted:
11
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
In Israel there is no registry of multiple sclerosis (MS), thus the prevalence of MS is unknown. Clalit Health Services (CHS) is Israel's largest health care organization. We have developed an algorithm to identify people with MS (PwMS) using CHS database and validated it against a gold-standard diagnosis by expert neurologists. People with a possible diagnosis of MS were identified in CHS database according to ICD-9 code or dispense of MS specific disease modifying treatment (DMT). The electronic medical records (EMRs) of a random sample of 25% of this population, stratified by age and sex were examined to determine positive predictive value (PPV). Another age- and sex- stratified random sample of 15% of pwMS under our care were searched in CHS database to determine database sensitivity (Sn). Finally, a random sample of 40% of people without MS were searched in CHS database to evaluate database specificity (Sp). The best case definition to retrieve pwMS was ICD-9 code 340 as an established diagnosis or at least one dispense of a DMT (PPV = 87%, Sn = 92%, Sp = 90%). Using this definition the prevalence of MS in Israel was 68, 82 and 95 per 100,000 population by the end of 2011, 2016 and 2021, respectively. The prevalence of MS in Israel is rising, in line with the worldwide trend.
Identifiants
pubmed: 39443627
doi: 10.1038/s41598-024-76282-4
pii: 10.1038/s41598-024-76282-4
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
25070Informations de copyright
© 2024. The Author(s).
Références
Reich, D. S., Lucchinetti, C. F. & Calabresi, P. A. Multiple sclerosis. N. Engl. J. Med. 378, 169–180 (2018).
doi: 10.1056/NEJMra1401483
pubmed: 29320652
pmcid: 6942519
Soelberg Sorensen, P. et al. The multiple sclerosis care unit. Multiple Scler. J. 25, 627–636 (2019).
doi: 10.1177/1352458518807082
Alter, M., Kahana, E., Zilber, N. & Miller, A. Multiple sclerosis frequency in Israel’s diverse populations. Neurology. 66, 1061–1066 (2006).
doi: 10.1212/01.wnl.0000204194.47925.0d
pubmed: 16606919
Widdifield, J. et al. Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada. Multiple Scler. J. 21, 1045–1054 (2015).
doi: 10.1177/1352458514556303
Bezzini, D. et al. Prevalence of multiple sclerosis in Tuscany (Central Italy): A study based on validated administrative data. Neuroepidemiology. 46, 37–42 (2016).
doi: 10.1159/000441567
pubmed: 26618996
Nelson, L. M. et al. A new way to estimate neurologic disease prevalence in the United States. Neurology. 92, 469–480 (2019).
doi: 10.1212/WNL.0000000000007044
pubmed: 30770422
pmcid: 6442012
Bargagli, A. M. et al. Prevalence of multiple sclerosis in the Lazio region, Italy: Use of an algorithm based on health information systems. J. Neurol. 263, 751–759 (2016).
doi: 10.1007/s00415-016-8049-8
pubmed: 26886201
pmcid: 4826660
Persson, R. et al. Multi-database study of multiple sclerosis: Identification, validation and description of MS patients in two countries. J. Neurol. 266, 1095–1106 (2019).
doi: 10.1007/s00415-019-09238-8
pubmed: 30778708
pmcid: 6469671
Al-Sakran, L. H., Marrie, R. A., Blackburn, D. F., Knox, K. B. & Evans, C. D. Establishing the incidence and prevalence of multiple sclerosis in Saskatchewan. Can. J. Neurol. Sci. 45, 295–303 (2018).
doi: 10.1017/cjn.2017.301
pubmed: 29557321
Culpepper, W. J. et al. Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 92, E1016–E1028 (2019).
doi: 10.1212/WNL.0000000000007043
pubmed: 30770432
pmcid: 6442008
Canova, C. et al. A systematic review of case-identification algorithms based on Italian healthcare administrative databases for three relevant diseases of the nervous system: Parkinson’s disease, multiple sclerosis, and epilepsy. Epidemiol. Prev. 43, 62–74. https://doi.org/10.19191/EP19.4.S2.P062.093 (2019).
doi: 10.19191/EP19.4.S2.P062.093
pubmed: 31650807
Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162–173 (2018).
doi: 10.1016/S1474-4422(17)30470-2
pubmed: 29275977
Spierer, R., Lavi, I., Bloch, S., Mazar, M. & Golan, D. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies. J. Neurol. 270, 4632–4639 (2023).
doi: 10.1007/s00415-023-11935-4
pubmed: 37589743
Cobo-Calvo, A. et al. Association of very early treatment initiation with the risk of long-term disability in patients with a first demyelinating event. Neurology 101, e1280–e1292 (2023).
doi: 10.1212/WNL.0000000000207664
pubmed: 37468284
pmcid: 10558169
Bunyan, R. F. & Pittock, S. J. Do not treat from CIS onset: Evaluate disease course and prognosis first – yes. Multiple Scler. J. 18, 391–393 (2012).
doi: 10.1177/1352458512440604
Preziosa, P., Rocca, M. A. & Filippi, M. Radiologically isolated syndromes: To treat or not to treat? J. Neurol. 271, 2370–2378 (2024).
doi: 10.1007/s00415-024-12294-4
pubmed: 38502339
Kołtuniuk, A. & Rosińczuk, J. Adherence to disease-modifying therapies in patients with multiple sclerosis. Patient Prefer Adherence. 12, 1557–1566 (2018).
doi: 10.2147/PPA.S175095
pubmed: 30197506
pmcid: 6112814
Calabrese, M. et al. Better explanations’ in multiple sclerosis diagnostic workup: A 3-year longitudinal study. Neurology. 92, e2527–e2537 (2019).
doi: 10.1212/WNL.0000000000007573
pubmed: 31043476
pmcid: 6659006
Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Scler. J. 26, 1816–1821 (2020).
doi: 10.1177/1352458520970841
Magyari, M. & Sorensen, P. S. The changing course of multiple sclerosis: Rising incidence, change in geographic distribution, disease course, and prognosis. Curr. Opin. Neurol. 32, 320–326 (2019).
doi: 10.1097/WCO.0000000000000695
pubmed: 30925518
Schwenkenbecher, P. et al. Impact of the McDonald Criteria 2017 on early diagnosis of relapsing-remitting multiple sclerosis. Front. Neurol. 10, 188 (2019).
doi: 10.3389/fneur.2019.00188
pubmed: 30930829
pmcid: 6428717
Sanai, S. A. et al. Aging and multiple sclerosis. Multiple Scler. J. 22, 717–725 (2016).
doi: 10.1177/1352458516634871
Periodic Survey of Health Care Services in Israel. (2021). https://www.btl.gov.il/Mediniyut/Situation/haveruth1/2021/Pages/capitatia_122021.aspx
Shmueli, A., Bendelac, J. & Achdut, L. Who switches sickness funds in Israel? Health Econ. Policy Law. 2, 251–265 (2007).
doi: 10.1017/S1744133107004100
pubmed: 18634649